Relationship between prescription and syndrome on mini-swine phlegm-stasis syndrome of coronary heart disease
10.16438/j.0513-4870.2017-0595
- VernacularTitle:小型猪痰瘀互结证冠心病的方证相应研究
- Author:
Lei LI
1
;
Jian-xun LIU
1
;
Jian-xun REN
1
;
Cheng-ren LIN
1
;
Yue SHI
1
;
Yan-lei MA
1
Author Information
1. Institute of Basic Medical Sciences of Xiyuan hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
- Publication Type:ORIGINAL ARTICLES
- Keywords:
correspondence between prescription and syndrome;
intermingled phlegm and blood-stasis;
Qi-Yin deficiency;
coronary disease;
miniature swine
- From:
Acta Pharmaceutica Sinica
2017;52(11):1698-1704
- CountryChina
- Language:Chinese
-
Abstract:
This study was conducted to investigate the effects of Danlou (correspondence between prescription and syndrome) tablet and Shengmai capsule (non-correspondence between prescription and syndrome) on mini-swine phlegm-stasis syndrome of coronary heart disease (CHD). 24 mini-swines were randomly divided into normal control group, model group, Danlou tablet group (0.24 g·kg-1) and Shengmai capsule group (0.14 g·kg-1). Phlegm-stasis syndrome of coronary heart disease was established by high-fat feeding and coronary intervention balloon injury. After 8 weeks of administration, blood lipid levels and blood rheology was detected. Echocardiography was used to examine the changes in heart function, and the extent of infarction was determined by nitro blue tetrazolium (NBT) staining method. The main symptoms, accompanied symptoms, tongue and pulse signs of the coronary heart disease mini-swine with phlegm-stasis syndrome were observed according to the symptom-graded scoring method. The results showed that Danlou tablet decreased serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) (P < 0.05 or P < 0.01), improved the blood rheology (P < 0.01) and cardiac function, increased the left ventricular ejection fraction (EF) and fraction shortening (FS) value (P < 0.05 or P < 0.01), reduced the myocardial infarction area/ventricular area (P < 0.01), significantly lowered the scores of four diagnosis in traditional Chinese medicine (P < 0.05 or P < 0.01). Shengmai capsule improved the hemorheology indices (P < 0.05 or P < 0.01), EF and FS value (P < 0.05), reduced the tongue and pulse signs scores (P < 0.05). However, Shengmai capsule failed to show therapeutic effects on blood lipid metabolism, the myocardial infarction area and primary symptom and syndrome score. The results suggest that as a drug for the treatment of Qi and Yin deficiency syndrome of CHD, Danlou tablet has limited therapeutic effects on phlegm-stasis syndrome of CHD. Only by the prescription correspondence with syndrome, using drug for the treatment of phlegm-stasis syndrome of CHD to treat phlegm-stasis syndrome of CHD, the prescription has a comprehensive therapeutic effect.
